I-Mab(NASDAQ:IMAB) 
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. It is developing Felzartamab (TJ202), a CD38 antibody th...
Website: https://www.i-mabbiopharma.com/
Founded: 2014
Full Time Employees: 229
CEO: Huaqiong Shen
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 0.68
H 0.70
L 0.59
C 0.68
V 378,557
10EMA 0.68
20EMA 0.68
60EMA 0.68
120EMA 0.68
250EMA 0.68